Compare CNXU & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXU | ACB |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 232.3M |
| IPO Year | 2025 | 2016 |
| Metric | CNXU | ACB |
|---|---|---|
| Price | $4.46 | $3.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 266.9K | ★ 1.5M |
| Earning Date | N/A | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.43 | $2.56 |
| 52 Week High | $13.66 | $6.67 |
| Indicator | CNXU | ACB |
|---|---|---|
| Relative Strength Index (RSI) | 26.71 | 54.25 |
| Support Level | N/A | $3.27 |
| Resistance Level | $10.41 | $3.91 |
| Average True Range (ATR) | 0.74 | 0.13 |
| MACD | -0.28 | -0.06 |
| Stochastic Oscillator | 1.97 | 3.75 |
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.